FDA Asks Leukemia Drug Maker to Suspend Sales over Blood Clot Dangers

person holding a tablet with the national trial lawyers news webpage on the screen

News Inferno; November 1, 2013

The U.S. Food and Drug Administration (FDA) just issued an updated Drug Safety Communication asking Ariad Pharmaceuticals, the maker of the leukemia drug, Iclusig (ponatinib), to suspend its marketing and sales following increased reports of serious blood clots in arteries and veins. Iclusig received FDA approval in December 2012.

The October 31, 2013 Communication is a follow-up to its prior announcement dated October 11, 2013.

The agency indicated that it would continue to evaluate Iclusig to better understand its risks-benefit profile, and advises patients currently being treated with Iclusig to speak to their heath care professionals concerning continuing treatment. Ariad Pharmaceuticals indicated that it agreed with the agency’s request.

Contact Us Today

Read More Legal News

The National Trial Lawyers White Logo for Footer
© Copyright 2022, All Rights Reserved | National Trial Lawyers
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram